Characterizing excision repair cross-complementing family genes as drug resistance biomarkers in breast cancer
Tóm tắt
Excision repair cross-complementing (ERCC) genes are important regulators of DNA repair processes, the aberrant expression of which may lead to treatment failures of breast cancer. The prognostic significance of the ERCC genes in several cancers has been investigated, except for breast cancer; therefore, we explored the ERCC genes, including ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, and ERCC8 in breast cancer, particularly during drug resistance processes. Using the 2021 provisional study of The Metastatic Breast Cancer Project from cBioPortal, we identified ERCC genetic alterations in 8–36% of patients, where most alterations were considered amplifications followed by deep deletions. Pathway enrichment analyses identified Wnt signaling enrichment which contributed to cell proliferation. ERCC2 had the highest epigenetic alteration levels at 7 DNA methylation sites. Also, the mRNA levels of ERCC1, ERCC2, ERCC4, ERCC6, and ERCC8 were higher in patients with breast cancer when compared to normal breast tissues, with higher ERCC2 but lower ERCC8 levels in metastatic breast tissues. Breast cancer patients with low ERCC6 levels had better overall survival rates than the groups with higher ERCC6 levels. ERCC1, ERCC2, and ERCC4 were identified as endocrine therapy response predictors. ERCC1 was specifically an antihuman epidermal growth factor receptor therapy predictor, and ERCC1, ERCC2, ERCC6, and ERCC8 were chemotherapy response predictors. We used bioinformatics to investigate and identify the roles of ERCC genes in breast cancer resistant cells, in particular ERCC1, ERCC2, and ERCC6. We also showed how the Wnt pathway and DNA repair processes had a role in drug resistance in breast cancer cells, but further studies are required to validate those results.
Tài liệu tham khảo
Kinnel B, Singh SK, Oprea-Ilies G, Singh R (2023) Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers 15(4):1320. https://doi.org/10.3390/cancers15041320
Landeros N, Castillo I, Pérez-Castro R (2023) Preclinical and clinical trials of new treatment strategies targeting cancer stem cells in subtypes of breast cancer. Cells 12(5):720. https://doi.org/10.3390/cells12050720
Yang F, He Q, Dai X, Zhang X, Song D (2023) The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies. Front Pharmacol 14:1143102. https://doi.org/10.3389/fphar.2023.1143102
Pecar G, Liu S, Hooda J, Atkinson JM, Oesterreich S, Lee AV (2023) RET signaling in breast cancer therapeutic resistance and metastasis. Breast Cancer Res 25(1):26. https://doi.org/10.1186/s13058-023-01622-7
Gu G, Dustin D, Fuqua SA (2016) Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol 31:97–103. https://doi.org/10.1016/j.coph.2016.11.005
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N et al (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res 25(1):62. https://doi.org/10.1186/s13058-023-01665-w
Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS et al (2016) DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 160:65–83. https://doi.org/10.1016/j.pharmthera.2016.02.003
Zhao M, Li S, Zhou L, Shen Q, Zhu H, Zhu X (2018) Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients. Life Sci 194:34–39. https://doi.org/10.1016/j.lfs.2017.12.018
Aiello M, Parra HS, Noto L, Restuccia N, Vigneri P, Paratore S (2017) P3.02c–090 The Role of ERCC-1 polymorphisms as predictive biomarker of response to nivolumab in advanced NSCLC: Topic: IT biomarkers. J Thorac Oncol 12(1):S1333. https://doi.org/10.1016/j.jtho.2016.11.1886
Wang H, Wang T, Guo H, Zhu G, Yang S, Hu Q et al (2016) Association analysis of ERCC5 gene polymorphisms with risk of breast cancer in Han women of northwest China. Breast Cancer 23(3):479–485. https://doi.org/10.1007/s12282-015-0590-2
Hu G, Li P, Cui X, Li Y, Zhang J, Zhai X et al (2018) Cr(VI)-induced methylation and down-regulation of DNA repair genes and its association with markers of genetic damage in workers and 16HBE cells. Environ Pollut 238:833–843. https://doi.org/10.1016/j.envpol.2018.03.046
Pasqui A, Boddi A, Campanacci DA, Scoccianti G, Bernini A, Grasso D et al (2022) Alteration of the nucleotide excision repair (NER) pathway in soft tissue sarcoma. Int J Mol Sci 23(15):8360
Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross-complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14(6):959–970
Felip E, Rosell R (2007) Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 7(3):261–268. https://doi.org/10.1586/14737159.7.3.261
Luo SS, Liao XW, Zhu XD (2018) Prognostic value of excision repair cross-complementing mRNA expression in gastric cancer. Biomed Res Int 2018:6204684. https://doi.org/10.1155/2018/6204684
Barroso-Sousa R, Forman J, Collier K, Weber Z, Jammihal T, Kao K et al (2022) Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit. JCO Precis Oncol. https://doi.org/10.1200/PO.21.00413
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL et al (2023) A gene panel associated with abemaciclib utility in ESR1-mutated breast cancer after prior cyclin-dependent kinase 4/6-inhibitor progression. JCO Precis Oncol 7:e2200532. https://doi.org/10.1200/PO.22.00532
Jain E, Zanudo JGT, McGillicuddy M, Abravanel DL, Thomas BS, Kim D et al (2023) The Metastatic Breast Cancer Project: leveraging patient-partnered research to expand the clinical and genomic landscape of metastatic breast cancer and accelerate discoveries. medRxiv. https://doi.org/10.1101/2023.06.07.23291117
Janeway KA, George S, Painter C, Cibulskis C, Cusher T, Doucette J et al (2023) Abstract 6084: The Osteosarcoma and leiomyosarcoma count me in projects of the cancer moonshot funded PE-CGS network directly engage patient participants in genomics research. Cancer Res 83(7):6084–6084. https://doi.org/10.1158/1538-7445.AM2023-6084
Lamba N, Cagney DN, Catalano PJ, Kim D, Elhalawani H, Haas-Kogan DA et al (2023) A genomic score to predict local control among patients with brain metastases managed with radiation. Neuro Oncol. https://doi.org/10.1093/neuonc/noad098
Li Z, McGinn O, Wu Y, Bahreini SA, Priedigkeit N, Ding K et al (2022) ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun 13:2011. https://doi.org/10.1038/s41467-022-29498-9
Lipsyc-Sharf M, Jain E, Collins LC, Rosenberg SM, Ruddy KJ, Tamimi RM et al (2023) Genomics of ERBB2-positive breast cancer in young women before and after exposure to chemotherapy plus trastuzumab. JCO Precis Oncol 7:e2300076. https://doi.org/10.1200/PO.23.00076
Parsons HA, Messer C, Santos K, Danysh BP, Hughes ME, Patel A et al (2023) Abstract 3874: Genomic mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in HER2+ metastatic breast cancer (HER2+ MBC). Cancer Res 83(7):3874–2874. https://doi.org/10.1158/1538-7445.AM2023-3874
Waks A, Kim D, Jain E, Snow C, Kirkner G, Rosenberg S et al (2022) Somatic and germline genomic alterations in very young women with breast cancer. Clin Cancer Res 28:2339–2348. https://doi.org/10.1158/1078-0432.CCR-21-2572
Zanudo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia J, et al. Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer. 2022.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404. https://doi.org/10.1158/2159-8290.Cd-12-0095
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. https://doi.org/10.1126/scisignal.2004088
Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J (2018) MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics 10(3):277–288. https://doi.org/10.2217/epi-2017-0118
Li C, Tang Z, Zhang W, Ye Z, Liu F (2021) GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res 49(W1):W242–W246. https://doi.org/10.1093/nar/gkab418
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98-w102. https://doi.org/10.1093/nar/gkx247
Bartha Á, Győrffy B (2021) TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci 22(5):2622. https://doi.org/10.3390/ijms22052622
Colwill K, Gräslund S (2011) A roadmap to generate renewable protein binders to the human proteome. Nat Methods 8(7):551–558. https://doi.org/10.1038/nmeth.1607
Győrffy B (2021) Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J 19:4101–4109. https://doi.org/10.1016/j.csbj.2021.07.014
Fekete JT, Győrffy B (2019) ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int J Cancer 145(11):3140–3151. https://doi.org/10.1002/ijc.32369
DiGiovanna JJ, Kraemer KH (2012) Shining a light on Xeroderma pigmentosum. J Investig Dermatol 132(3, Part 2):785–796. https://doi.org/10.1038/jid.2011.426
Kamileri I, Karakasilioti I, Garinis GA (2012) Nucleotide excision repair: new tricks with old bricks. Trends Genet 28(11):566–573. https://doi.org/10.1016/j.tig.2012.06.004
Menck CF, Munford V (2014) DNA repair diseases: What do they tell us about cancer and aging? Genet Mol Biol 37:220–233
Nouspikel T (2008) Nucleotide excision repair and neurological diseases. DNA Repair 7(7):1155–1167. https://doi.org/10.1016/j.dnarep.2008.03.015
Karimaian A, Majidinia M, Bannazadeh Baghi H, Yousefi B (2017) The crosstalk between Wnt/β-catenin signaling pathway with DNA damage response and oxidative stress: implications in cancer therapy. DNA Repair 51:14–19. https://doi.org/10.1016/j.dnarep.2017.01.003
Pasadi S, Muniyappa K (2020) Evidence for functional and regulatory cross-talk between Wnt/β-catenin signalling and Mre11-Rad50-Nbs1 complex in the repair of cisplatin-induced DNA cross-links. Oncotarget 11(44):4028–4044. https://doi.org/10.18632/oncotarget.27777
Abreu de Oliveira WA, Moens S, El Laithy Y, van der Veer BK, Athanasouli P, Cortesi EE et al (2021) Wnt/β-catenin inhibition disrupts carboplatin resistance in isogenic models of triple-negative breast cancer. Front Oncol 11:705384. https://doi.org/10.3389/fonc.2021.705384
Yang Y, Li X, Hao L, Jiang D, Wu B, He T et al (2020) The diagnostic value of DNA repair gene in breast cancer metastasis. Sci Rep 10(1):19626. https://doi.org/10.1038/s41598-020-76577-2
Zhang W, Guo N, Yu C, Wang H, Zhang Y, Xia H et al (2012) Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumor Biol 33(6):2209–2216. https://doi.org/10.1007/s13277-012-0482-4
Zhang Y, Zhang D, Wang H (2018) Research on correlations of ERCC-1 with proliferation and apoptosis of ovarian cancer cells. JBUON 23:1753–1795
Lee S-A, Lee K-M, Park W-Y, Kim B, Nam J, Yoo K-Y et al (2005) Obesity and genetic polymorphism of ERCC2 and ERCC4 as modifiers of risk of breast cancer. Exp Mol Med 37(2):86–90. https://doi.org/10.1038/emm.2005.12
Qian T, Zhang B, Qian C, He Y, Li Y (2017) Association between common polymorphisms in ERCC gene and glioma risk: a meta-analysis of 15 studies. Medicine 96(20):e6832. https://doi.org/10.1097/md.0000000000006832
Li J, Liu S, Wang W, Zhang K, Liu Z, Zhang C et al (2014) ERCC polymorphisms and prognosis of patients with osteosarcoma. Tumour Biol 35(10):10129–10136. https://doi.org/10.1007/s13277-014-2322-1
Burgess JT, Rose M, Boucher D, Plowman J, Molloy C, Fisher M et al (2020) The Therapeutic potential of DNA damage repair pathways and genomic stability in lung cancer. Front Oncol 10:1256. https://doi.org/10.3389/fonc.2020.01256
Li QQ, Lee RX, Liang H, Wang G, Li JM, Zhong Y et al (2013) β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol 43(3):721–728. https://doi.org/10.3892/ijo.2013.1996
Piljić Burazer M, Mladinov S, Matana A, Kuret S, Bezić J, Glavina DM (2019) Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages—a single-center study. Diagn Pathol 14(1):105. https://doi.org/10.1186/s13000-019-0885-2
Wei X, Yang J (2015) Relationship between ERCC1, Ki67, PCNA expression with anthracycline chemo-therapeutic drugs′ sensitivity in breast cancer tissues. Chin J Immunol 12:169–172
Baiomy MAE, El Kashef WF (2017) ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy. Asian Pacific J Cancer Prev 18(2):507–513. https://doi.org/10.22034/apjcp.2017.18.2.507